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Abstract− A new series of fentanyl derivatives (i.e. N-[1-(2-phenethyl)-4-piperidyl]-N-
(guanidinoalkyl)propanamide) bearing aliphatic alkaneguanidinium moieties were prepared. 
Their affinities for the µ opioid receptors and for the I2-imidazoline binding sites (I2-IBS) 
were determined on human post-mortem prefrontal cortex membranes. All of these hybrid 
compounds had significant and/or very high affinity for both receptors in the nanomolar 
range, meaning an improvement compared to the prototype N-[1-(2-phenethyl)-4-piperidyl]-
N-(guanidinopropyl)propanamide previously reported. 
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Several pharmacological studies revealed the interactions between I2-imidazoline binding site 
(IBS) and opioid systems.
1-4
 Very recently, it has been shown that 2-BFI, an I2-IBS ligand, 
when chronically administrated, led to an attenuation of both the hyperactivity of rat locus 
coeruleus neurons during opiate withdrawal and the development of tolerance to morphine.
5
 
Other studies demonstrated the potential of the putative endogenous IBS ligand agmatine
6
 (1-
amino-4-guanidinobutane) to attenuate the escalation of intravenous cocaine and fentanyl 
self-administration in rats
7
 and to regulate morphine tolerance/dependence and withdrawal 
symptoms.
8
 Thus, I2-IBS ligands might be useful agents for the management of opioid 
dependence and tolerance. 
 
One approach that seems interesting and promising for pharmaceutical regulation of opioid 
dependence and tolerance is the use of hybrid drugs in which opioid (e.g. fentanyl) and I2-
imidazoline agents (e.g. guanidine group) are combined in one molecule. Among structure-
activity relationships (SAR) that have been published earlier, studies on the replacement of 
the phenyl ring of fentanyl by a butyl or propyl group afforded µ-opioid molecules that 
retained some analgesic activity of the parent compound.
9
 
 
A first attempt to obtain hybrid molecules with opioid activity and I2-IBS affinity led us to 
identify the prototype 5e (Scheme 1).
10
 This compound displayed high affinity for the µ 
opioid receptor whereas it only showed low affinity for the I2-IBS. 
In a previous SAR studies of a series of alkane bisguanidinium aliphatic derivatives,
11
 we 
found out that increasing the number of methylene units between two guanidine moieties led 
to an increase of the I2-IBS affinity. We rationalised that modulating the chain length of the 
methylenic spacer between the fentanyl pharmacophore and the guanidine moiety should 
increase the affinity of the prototype 5 for I2-IBS. Hence, a new series of fentanyl hybrids 
compounds bearing a guanidine at the end of a methylene chain of 2, 6, 8 and 12 units was 
prepared (Scheme 1) and their binding affinity to both kinds of receptors was evaluated.  
 
Chemistry 
Compounds 1e-4e were synthesised in 6 steps using a shorter procedure than the one 
previously described by Montero et al.
10
 The mono Boc-protected diaminoalkanes (m = 2, 6, 
8 and 12) were directly reacted with 1-phenethyl-4-piperidone in the presence of NaBH3CN 
maintaining the pH at ca 7-8 with AcOH. The resulting amines (1a-4a) were acylated with 
propionic anhydride/DMAPcat./pyridine/CH2Cl2 to afford the corresponding propanamides 1b-
 5 
4b which were easily isolated by flash chromatography.
12
  Following the removal of the Boc-
protecting group, the guanidines were introduced with the classical Boc-thiourea reagent.
13
 
Compounds 1e-4e were finally isolated as their trifluoroacetate salt and purified by 
crystallisation.
14
 The NMR spectra of these series of propanamides (1b-e to 4b-e) show 
characteristic duplicated signals corresponding to the observation of the cis-trans isomerism 
around the N-CO bond as previously reported for 5e.
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Reagents and conditions. (i) Amine (5 eq.), Boc2O (1 eq.), CHCl3, rt; (ii) NaBH3CN, MS (3Å), MeOH, rt;
(iii) (EtCO)2O, DMAP, Pyridine, CH2Cl2, rt; (iv) CF3CO2H, CH2Cl2, 30 min; (v) HgCl2, Et3N, CH2Cl2, rt  
 
 
Pharmacology 
The binding affinity of the new synthesised compounds (1e-4e) and 5e was evaluated through 
competition binding studies against the selective I2-IBS radioligand [
3
H]-2-BFI and the 
selective µ-opioid ligand [3H]-DAMGO following the procedure previously 
described.
10,11,15,16
 The assays were performed in membranes from post-mortem human 
frontal cortex, a brain area that shows an important density of I2-IBS and µ-opioid receptors. 
Drug competition studies were performed with either [
3
H]-2-BFI (1 nM) or [
3
H]-DAMGO (2 
nM) in the absence or presence of various concentrations of competing drugs (10
-12
, 10
-10
 and 
10
-3
 M concentrations). Non-specific binding was estimated in the presence of 10
-3
 M 
 6 
idazoxan in experiments with [
3
H]-2-BFI, or with 10
-4
 M naloxone in [
3
H]-DAMGO assays. 
The opioid agonist fentanyl and the α2-adrenergic/I2-IBS ligand idazoxan were used as 
references (Table 1). Compounds 1e-5e were studied as their trifluoroacetate salts. 
 
All the new compounds synthesised (1e-4e) showed submicromolar to nanomolar affinity for 
I2-IBS which represented a raise from 4- (1e) to almost 300-fold (4e) compared to the 
prototype 5e (Table 1). Remarkably, compound 4e, with a 12 methylene units spacer between 
the propanamide and guanidine groups, was a more potent ligand than idazoxan (Ki = 28 nM) 
for I2-IBS with Ki = 6.5 nM. In this series, we observed a good correlation between the 
number of methylene units in the spacer and the affinity for I2-IBS.  
  
Table 1. Affinity data [Ki (nM)] for I2-IBS and µ-opioid receptors. 
Compound -(CH2)m- 
m
a
 
[
3
H]-2BFI 
I2 
[
3
H]-DAMGO 
µ 
n
b
 
 
Idazoxan -- 28±11 ndc 5 
Fentanyl -- 5462±1343d 2.9±1.5 4 
1e 2 437±228 433±83 3 
5e 3 1920±996 23±4.5 3 
2e 6 409±238 1.04±0.28 3 
3e 8 126±72 37±9.7 3 
4e 12 6.5±3.0 477±75 3 
a 
Number of methylene units in the spacer;
b
 Values expressed as mean ± standard error mean of n 
experiments;
c
 Not determined; 
d 
Ki value for mouse brain membrane( from reference 10) 
 
The clear improvement in I2-IBS binding affinity observed when increasing the number of 
methylene units from m = 3 (5e) to m = 12 (4e) was in agreement with our previous 
observations on alkane bis-guanidinium compounds in which the affinity for I2-IBS increased 
with the chain length. However, in that study, the presence of both guanidinium at the end of 
the aliphatic chain appeared essential for I2-IBS activity since monoguanidinium counterparts 
(e.g. octyl, nonyl and dodecylguanidinium) showed extremely poor I2-IBS affinity.
11
 Thus, in 
the case of the hybrid molecules 1e-5e, it is interesting to note that the presence of the 
piperidyl propanamide pharmacophore proceeding from the fentanyl structure confers 
significant I2-IBS affinity to the alkyl guanidinium moiety. Since fentanyl alone is a very poor 
I2-IBS ligand (see Table 1), there is some evidence for a possible synergic effect of both 
pharmacophoric groups for I2-receptor affinity in these hybrid compounds.  
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Regarding µ-opioid receptor, all the molecules bound with affinities in the nanomolar range 
(Table 1). One compound (3e, Ki = 37 nM) was roughly equipotent with 5e (Ki = 23 nM), two 
molecules (1e, 4e) showed lower affinity whereas 2e (Ki = 1.04 nM) was an excellent µ-
opioid ligand with a binding affinity comparable to that of fentanyl (2.9 nM). 
With respect to the spacer chain length, these results showed that the best µ-opioid ligand was 
obtained with six methylene units (2e, m = 6) whereas either increasing (m = 8, 12) or 
decreasing (m = 2, 3) the length of the spacer affords less potent molecules. This observation 
would need confirmation by the assay of more spacers of different lengths (e.g. m = 4, 5, 7, 
9).  
 
To conclude, we have reported a new series of N-[1-(2-phenethyl)-4-piperidyl]-N-
(guanidinoalkyl)propanamide hybrid molecules with improved affinity for the I2-IBS and µ-
opioid receptor compared to the prototype 5e.  
 This study showed that the incorporation in a same molecule of µ-opioid and I2-IBS 
pharmacophoric moieties (i.e. fentanyl and alkylguanidine respectively), linked by a 
methylene spacer, led to a synergistic effect for the binding to both receptors. The modulation 
of the affinity for both receptors by modification of the length of the methylene spacer 
between the two pharmacophoric moieties afforded two hybrid compounds (1e and 3e) with 
balanced I2/µ affinity, a 400-fold µ-opioid selective compound (2e) and an 80-fold I2-IBS 
selective compound (4e). The in vitro and in vivo functional activity of these new dual acting 
drugs is currently being evaluated and will be reported elsewhere.  
Finally, these results are relevant in the field of IBS since they further demonstrate that 
aliphatic alkaneguanidines can afford high affinity ligands for the I2-IBS.  
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